The Plasmodium proteasome (Pf20S) emerged as a target for antimalarials. Pf20S inhibitors are active at multiple stages of the parasite life cycle and synergize with artemisinins, suggesting that Pf20S inhibitors have potential to be prophylactic, therapeutic, transmission blocking as well as useful for combination therapy. We recently reported asparagine ethylenediamines (AsnEDAs) as immunoproteasome inhibitors and modified AsnEDAs as selective Pf20S inhibitors. Here we report further structure-activity relationship study of AsnEDAs for selective inhibition of Pf20S over human proteasomes. Additionally, we show a new mutation that conferred resistance to AsnEDAs and collateral sensitivity to an inhibitor of the Pf20S β2 subunit, same as previously identified resistant mutation. This resistance could be overcome through the use of structureguided inhibitor design. Collateral sensitivity to inhibitors among respective proteasome subunits *
Proteasomes of pathogenic microbes have become attractive targets for anti-infectives. Coevolving with its human host, Mycobacterium tuberculosis (Mtb) has developed mechanisms to resist host-imposed nitrosative and oxidative stresses. Genetic deletion or pharmacological inhibition of the Mtb proteasome (Mtb20S) renders nonreplicating Mtb susceptible to reactive nitrogen species in vitro and unable to survive in the lungs of mice, validating the Mtb proteasome as a promising target for anti-Mtb agents. Using a structure-guided and flow chemistry-enabled study of structure−activity relationships, we developed phenylimidazole-based peptidomimetics that are highly potent for Mtb20S. X-ray structures of selected compounds with Mtb20S shed light on their selectivity for mycobacterial over human proteasomes.
Treatment of tuberculosis (TB) currently
takes at least 6 months.
Latent Mycobacterium tuberculosis (Mtb)
is phenotypically tolerant to most anti-TB drugs. A key hypothesis
is that drugs that kill nonreplicating (NR) Mtb may shorten treatment
when used in combination with conventional drugs. The Mtb proteasome
(Mtb20S) could be such a target because its pharmacological inhibition
kills NR Mtb and its genetic deletion renders Mtb unable to persist
in mice. Here, we report a series of macrocyclic peptides that potently
and selectively target the Mtb20S over human proteasomes, including
macrocycle 6. The cocrystal structure of macrocycle 6 with Mtb20S revealed structural bases for the species selectivity.
Inhibition of 20S within Mtb by 6 dose dependently led
to the accumulation of Pup-tagged GFP that is degradable but resistant
to depupylation and death of nonreplicating Mtb under nitrosative
stress. These results suggest that compounds of this class have the
potential to develop as anti-TB therapeutics.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.